Kurzfassung

An open-label, phase 2a/2b study of KRT-232 in subjects with Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (post PV-MF), or Post Essential Thrombocythemia MF (post ET-MF) who have failed Ruxolitinib - KRT-232-101